Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.77 |
| ▸ | USP2 | O75604 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | BLM | P54132 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | THRB | P10828 | 4/20 | 0.48 |
| ▸ | RECQL | P46063 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 3/20 | 0.44 |
| ▸ | GABRD | O14764 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972557 | 0.93 | FTO (0.76) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL3109289 | 0.90 | FTO (0.78) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL31435692 | 0.90 | FTO (0.78) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL24274861 | 0.88 | FTO (0.76) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL10260320 | 0.88 | FTO (0.76) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL21129885 | 0.88 | FTO (0.74) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL18972336 | 0.88 | FTO (0.74) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL10205564 | 0.87 | FTO (1.00) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL22702333 | 0.86 | FTO (0.71) | FTOUSP2MEN1KMT2ABLM | |
| SCHEMBL21126672 | 0.86 | FTO (0.71) | FTOUSP2MEN1KMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160223559-A1 | TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-04 | — | — | US | disclosed |
| US-20160223559-A1 | TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160223559-A1 | TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF | HCK, TTK, TLK1 | FTO 2591/4885USP2 620/4885MEN1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.